Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer.

Trial Profile

Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms FIRIS
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 06 Jul 2011 Actual end date changed from Nov 2011 to Mar 2012 as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Primary endpoint 'Progression-free-survival-duration' has been met.
    • 07 Jun 2011 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top